deaths (OS)progression or deaths (PFS)RFS/DFS

metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)

versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 -420 [-2369; 1528] /10000
21/49 vs. 24/51
-1257 [-2605; 92] /10000
39/49 vs. 47/51
-
versus pegylated liposomal doxorubicin
avelumab alone vs. pegylated liposomal doxorubicin 1 324 [-675; 1324] /10000
109/188 vs. 104/190
1613 [742; 2483] /10000
154/188 vs. 125/190
-
avelumab plus pegylated liposomal doxorubicin vs. pegylated liposomal doxorubicin 1 -48 [-1052; 956] /10000
102/188 vs. 104/190
549 [-386; 1483] /10000
134/188 vs. 125/190
-